
|Articles|January 15, 2006
Topical glaucoma agent offers real IOP reduction in study
Plymouth, England—Latanoprost (Xalatan, Pfizer Ophthalmics), a potent topical ocular antihypertensive agent, does not seem to cause changes in the central corneal thickness after 2 months of follow-up. This result contradicts previous studies that reported a statistically significant decrease in the central corneal thickness, according to George D. Pappas, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
AAO 2025: Understanding and diagnosing endophthalmitis
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5